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Two-year Rehospitalization Rates of Patients with Newly Diagnosed 
or Chronic Schizophrenia on Atypical or Typical Antipsychotic Drugs: 
Retrospective Cohort Study
Aim To determine if atypical antipsychotic agents reduce the rehospital-
ization rates of patients with newly diagnosed or chronic schizophrenia 
in comparison with typical antipsychotic drugs.
Methods From January 1, 2003, to December 31, 2004, we retrospective-
ly compared two-year rehospitalization rates of 135 patients with newly 
diagnosed schizophrenia and 398 patients with chronic schizophrenia 
(62% and 65% men, respectively), who were initially discharged from 
Vrapče Psychiatric Hospital, Zagreb, with the prescription of atypical 
(olanzapine, risperidone or clozapine) or typical (haloperidol or fluphen-
azine) antipsychotic treatment between January 1, 2002 and December 
31, 2002. Time-to-readmission was determined with Kaplan-Meier for-
mula for survival analysis.
Results In the two-year follow-up, 52 (39%) newly diagnosed patients 
and 197 (47%) patients with chronic schizophrenia were rehospitalized. 
No significant differences in time-to-rehospitalization were observed 
with respect to the type of medications in patients with newly diag-
nosed schizophrenia (P = 0.378) or patients with chronic schizophrenia 
(P = 0.531).
Conclusions. Rehospitalization rates of patients who were prescribed 
atypical antipsychotic drugs were similar to those of patients who were 
prescribed typical antipsychotic drugs for both the group with the first 
psychotic episode and group with chronic schizophrenia.
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Although antipsychotic agents have been in 
use for the treatment of schizophrenia for 
over 50 years, the individual patient outcome 
is still far from satisfactory. In most patients, 
schizophrenia has a chronic course character-
ized by frequent relapses, ie, exacerbation of 
psychotic symptoms and the need for rehos-
pitalization (1-3).
Relapse prevention seems to be crucial for 
a beneficial long-term outcome. Successive 
relapses have a negative impact on duration 
of illness and the level of remission, causing 
higher degree of disability and refractoriness 
to treatment (4). Relapse could be defined as 
worsening of psychotic symptoms and behav-
ior that puts the patients or their environment 
at risk of serious damage or even death. Al-
though not ideal, the time between two hospi-
talizations is the most frequently used measure 
of relapse rate (5-8).
Antipsychotic drugs can prevent relapse in 
individuals with schizophrenia. Relapse pre-
vention strongly depends on patient compli-
ance, which may be reduced due to unpleasant 
side effects of antipsychotic drugs (9). Typical 
antipsychotic drugs often cause extrapyramidal 
side effects, such as dystonic reactions, akathi-
sia, and persistent pseudoparkinsonism. Atyp-
ical antipsychotic medications, on the other 
hand, often lead to weight gain, glucose intol-
erance, hyperlipidemia, serious hematologi-
cal disturbances, prolongation of QT interval, 
and stroke in older patients (10,11).
Previous research has shown that atypical 
antipsychotic drugs directly reduce the rate of 
rehospitalization (12-17). Given that hospi-
talization costs make a large part of the overall 
cost of schizophrenia treatment (18), reduction 
in hospitalization rates would considerably de-
crease the overall costs of the treatment (19).
As new antipsychotic agents enter the mar-
ket, it is important to compare their benefits 
with those of typical antipsychotic medica-
tions (20-22). In Croatia, all typical antipsy-
chotic drugs and clozapine had become avail-
able before 1995. Risperidone became available 
in 1994 and olanzapine in 1996. A prelimi-
nary analysis performed for our in-house needs 
showed that the number of hospitalized schizo-
phrenic patients in our hospital has decreased 
by 8.4% since the introduction of atypical an-
tipsychotic drugs in 1995. Several studies have 
shown lower rehospitalization rates of patients 
with schizophrenia who take atypical antipsy-
chotic drugs (12-17). On the other hand, Patel 
et al (23) found lower rehospitalization rates 
of patients who received typical antipsychot-
ic drugs. Other studies found no differences in 
rehospitalization rates between patients pre-
scribed atypical and typical antipsychotic drugs 
(5,7). However, in most of these studies the 
patients were not followed-up for more than 
a year and the effects of antipsychotic drugs 
on rehospitalization rates after the first year of 
treatment were not investigated.
The aim of our study was to determine if 
atypical antipsychotic agents, ie, olanzapine, 
risperidone, or clozapine, reduce the rehos-
pitalization rates of patients with newly diag-
nosed or chronic schizophrenia in comparison 
with typical antipsychotic drugs, ie, haloperi-
dol or fluphenazine.
Patients and methods
Design and setting
From January 1, 2003 to December 31, 2004 
we retrospectively determined rehospitaliza-
tion rate in patients with schizophrenia who 
were discharged from Vrapče Psychiatric Hos-
pital, Zagreb, in 2002.
Patient data were collected from Vrapče 
Psychiatric Hospital database of medical re-
cords. The hospital serves a greater part of the 
city of Zagreb and the surrounding area, as 
well as other parts of the country. It admits 
around 7000 patients a year and has a com-
plete patient database. To identify the patients 
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who were possibly rehospitalized over the two-
year follow-up period in health care institu-
tions other than Vrapče Psychiatric Hospital, 
we searched the National Register for Psycho-
ses. The Register is maintained by the Croa-
tian National Institute of Public Health and 
contains records of all hospital admissions of 
patients with psychotic disorders to any health 
care institution with mental health service in 
Croatia.
Patients
To be included in the study, patients had to be 
between 18 and 65 years old, discharged from 
the hospital between January 1 and December 
31, 2002, with the diagnosis of schizophrenia 
(newly diagnosed or chronic) and prescribed 
atypical (olanzapine, risperidone or clozapine) 
or typical (haloperidol or fluphenazine) anti-
psychotic treatment. In our study we divided 
new and chronic schizophrenic patients. Di-
agnosis of schizophrenia was established by li-
censed psychiatrists according to international 
classification manuals, International Classifi-
cation of Diseases – version 10 and Diagnos-
tic and Diagnostic and Statistical Manual of 
Mental Disorders – 4th edition (24,25). In 
our research we did not separate the patients 
according to subtype of schizophrenia. Anti-
psychotic medication was prescribed by psy-
chiatrists on the ward according to clinical 
presentation of patients. Of 831 patients who 
met these criteria, we excluded those who were 
transferred to another hospital due to a gener-
al medical condition (n = 18), those who were 
hospitalized for more than 365 days (n = 73), 
and those included in randomized controlled 
trials (n = 8). We also excluded the patients 
who were taking a combination of antipsy-
chotic drugs (n = 199). The remaining 533 pa-
tients (192 women and 341 men) were includ-
ed in the analysis and divided in two groups, 
one consisting of 135 patients with newly di-
agnosed schizophrenia and the other consist-
ing of 398 patients with chronic schizophre-
nia (Figure 1).
Data collection
Data on sex, age, age at illness onset, duration 
of hospitalization in 2002, number of previ-
ous hospitalizations, and antipsychotic dose 
at discharge were collected from the hospi-
tal medical records. Time-to-rehospitalization 
was measured as the time from the initial dis-
charge in 2002 to the admittance to either our 
hospital or some other psychiatric facility dur-
ing the 2003-2004 follow-up period. Data on 
rehospitalization of patients admitted to some 
psychiatric institution other than Vrapče Psy-
chiatric Hospital during the study period were 
obtained from the National Register of Psy-
choses.
All patients included in the study were 
prescribed medical treatment after being dis-
charged from the hospital and were not pro-
vided any additional special care or therapy. 
Rehospitalizations of these patient were fol-
lowed up for 2 years, ie, from January 1, 2003 
to December 31, 2004.
The Ethical Committee of the hospital ap-
proved the conduct of the study, in accordance 
with the 1964 Helsinki declaration.
Figure 1. Flow diagram of patients with schizophrenia discharged 
from Vrapče Psychiatric Hospital between January 1 and December 
31, 2002.
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Statistical analysis
Standard descriptive statistics was used to de-
scribe the demographic and clinical character-
istics of the patients. Frequency tables were 
calculated for categorical variables. Since con-
tinuous data were not normally distributed, 
medians with interquartile ranges were cal-
culated for age, age at illness onset, number 
of hospitalizations, duration of hospitaliza-
tion, time to rehospitalization, and the dose 
of antipsychotic medication. Differences in 
proportion of men and women between the 
study groups were compared with the Man-
tel-Haenszel test χ2 test. Differences in con-
tinuous variables between the study groups 
were assessed with the Man-Whitney U test 
or Kruskal-Wallis Anova, as appropriate. To 
measure the time to readmission, we used the 
survival analysis. Survival curves were estimat-
ed by the product-limit (Kaplan-Meier) for-
mula. The significance of differences between 
groups was measured by the multiple-sam-
ple test (multiple groups) and the Cox F-Test 
(two groups). Cox regression model was used 
to evaluate the impact of age, number of hos-
pitalizations, and the duration of the previous 
hospitalization on survival curves. All statisti-
cal tests were two-tailed, and P<0.05 was con-
sidered significant. All tabulations and statis-
tical analysis were performed with Statistica, 
version 5.5 for Windows (StatSoft Inc. Tulsa, 
OK, USA).
Results
In the group patients with newly diagnosed 
schizophrenia, 72 were on typical and 63 were 
on atypical antipsychotic medications. In 
this group, 22% of patients were taking halo-
peridol, 31% fluphenazine, 19% risperidone, 
19% olanzapine, and 10% clozapine (Ta-
ble 1). Different treatment subgroups signif-
icantly differed in their age, age at the onset 
of schizophrenia, and duration of hospitaliza-
tion. Younger patients were more often treat-
ed with atypical antipsychotic medications, 
ie, olanzapine or risperidone, than older pa-
tients, (Table 1). Patients with earlier onset 
of schizophrenia were significantly more of-
ten prescribed risperidone than fluphenazine. 
The duration of hospitalization was longest in 
patients taking olanzapine and shortest in the 
patients taking fluphenazine (Table 1).
In the group of patients with chron-
ic schizophrenia, 33% were taking haloperi-
dol, 25% fluphenazine, 17% risperidone, 10% 
olanzapine, and 15% clozapine (Table 2). In 
this group, there were significantly more men 
than women. The patients taking typical anti-
psychotic medications, ie, haloperidol or flu-
phenazine, were significantly older than pa-
tients taking other antipsychotic drugs. No 
significant difference was found between the 
treatment subgroups in the age of onset of 
schizophrenia or the number of previous hos-
pitalizations (Table 2). The duration of hospi-
Table 1. Demographic and clinical characteristics of patients with newly diagnosed schizophrenia discharged from Vrapče Psychiatric 
Hospital, Zagreb, in 2002
Treatment groups of antipsychotic drugs
typical atypical
Characteristics
Total
(n = 135)
haloperidol
(n = 30)
fluphenazine
(n = 42)
risperidone
(n = 25)
olanzapine
(n = 25)
clozapine
(n = 13) P*
No. (%) of men  82 (61.0)  19 (63.0)  26 (62.0)  16 (64.0)  11 (44.0)  10 (77.0) 0.330
Age (years; median, IQ)†  31 (23-43)  36.5 (22-37)  38 (27-47)  24 (20-32)  27 (22-39)  33 (27-46) 0.014‡
Age at illness onset (years; median, IQ)  27 (22-36)  28 (22-37)  32.5 (24-41)  23 (20-28)  26 (21-34)  26 (22-29) 0.007‡
Duration of hospitalization (days; median, IQ)  33 (18.5-58.5)  30 (14-60)  25 (11-39)  33 (26-60)  46.5 (27-70)  40 (29-58) 0.015‡
Time to rehospitalization (days; median, IQ) 775 (333-936) 735 (242-936) 805 (661-995) 768 (524-936) 825 (352-878) 762 (71-804) 0.378‡
Dose (mg/d)  13,5 (6-20)   7.5 (5-15)   4 (4-6)  10 (10-15) 250 (200-300)   –
*Mantel-Haenszel test χ2 test.
†IQ – interquartile (25%-75%) range.
‡Man-Whitney U test.
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talization was longest for the patients taking 
olanzapine, and the shortest for the patients 
taking clozapine.
Of 135 patients who were newly diag-
nosed with schizophrenia, 36 (27%) were re-
hospitalized in the first year and 52 (39%) 
in the second year of follow-up. There were 
27 of 72 patients taking typical antipsychot-
ic medications and 25 of 63 patients taking 
atypical antipsychotic medications who were 
rehospitalized in the two-year period. Of 
these 52 patients, 14 were taking haloperidol, 
13 fluphenazine, 9 risperidone, 10 olanzap-
ine, and 6 clozapine. The patients on clozap-
ine were rehospitalized more often than other 
groups during the first year of follow-up, but 
after two years no significant difference in the 
rehospitalization rate was found among dif-
ferent treatment groups of patients newly di-
agnosed with schizophrenia (Figure 2). Dur-
ing the first year of follow-up, patients on 
atypical antipsychotic medications were re-
hospitalized less often than patients on typi-
cal antipsychotic medications, but during the 
second year of follow-up, this difference dis-
appeared (Figure 3). The longest period be-
tween discharge and first rehospitalization 
was found in the patients taking olanzapine, 
and the shortest in the patients taking halo-
peridol, but the difference between them was 
not significant (Table 1).
Of 389 patients with chronic schizophre-
nia, 193 (48%) were rehospitalized during 
the first year of follow-up. By the end of the 
second year of follow-up, the number of re-
hospitalized patients increased only by 4. Of 
197 (49%) patients rehospitalized during the 
follow-up, 61 (31%) were taking haloperi-
dol, 59 (31%) fluphenazine, 26 (13%) risper-
Table 2. Demographic and clinical characteristics of patients with chronic schizophrenia discharged from Vrapče Psychiatric Hospital, 
Zagreb, in 2002
Treatment groups of antipsychotic drugs
typical atypical
Characteristics
Total
(n = 398)
haloperidol
(n = 130)
fluphenazine
(n = 101)
risperidone
(n = 67)
olanzapine
(n = 40)
clozapine
(n = 60) P
No. (%) of men 259 (65.0) 101 (78.0)  58 (57.0)  43 (64.0)  21 (53.0)  36 (60.0)  0.004*
Age (years; median, IQ)†  42 (35-49)  44 (38-50)  44 (38-51)  38 (30-45)  36 (28.5-44.0)  40 (33.5-47.5) <0.001‡
Age at illness onset (years; median, IQ)  27 (24-33)  27 (24-34)  28 (24-32)  30 (22-34)  28 (23.5-32)  26 (23.5-31)  0.688‡
No. of hospitalizations (median, IQ)   6 (3-10)   6 (3-10)   7 (3-11)   5 (3-7)   4.5 (3-8)   6 (4-10)  0.103‡
Duration of hospitalization (days; median, IQ)  43 (23-69)  46 (26-80)  36 (21-59)  38.5 (17-54)  59.5 (43.5-96.5)  35 (24.0-68.5)  0.001‡
Time to rehospitalization (days; median, IQ) 410 (147-820) 485.5 (2-1083) 334 (157-820) 594 (194-794) 424 (16-1083) 456.5 (116.0-843.5)  0.531‡
Dose (mg/d; median, IQ)  20 (15-30)   7.5 (5-15)   4 (3-6)  15 (10.0-17.5) 200 (150-300)    –
*M-L χ2 test.
†IQ – interquartile (25%-75%) range.
‡Man-Whitney U test.
Figure 2. Time to rehospitalization of patients with newly diagnosed 
schizophrenia who were discharged on typical antipsychotic drugs flu-
phenazine (dashed line) or haloperidol (full line), or atypical antipsy-
chotic drugs risperidone (dotted line), olanzapine (short-/long-dashed 
line), or clozapine (long-dashed line).
Figure 3. Time to rehospitalization of patients with newly diagnosed 
schizophrenia discharged on typical (full line) or atypical antipsychotic 
medications (dashed line).
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idone, 24 (12%) olanzapine, and 27 (14%) 
clozapine. The proportion of rehospitalized 
patients in each treatment group was not sig-
nificantly different during the first year of 
follow-up and there were no changes in the 
rehospitalization rate in the second year of 
follow-up (Figure 4). By the end of the two-
year follow-up period, 120 (61%) patients 
taking typical antipsychotic drugs (haloperi-
dol or fluphenazine) and 77 (39%) patients 
taking atypical antipsychotics (risperidone, 
olanzapine or clozapine) were rehospitalized 
(Figure 5). Among the patients with chronic 
schizophrenia, the longest period to first re-
hospitalization was found in patients on ris-
peridone and the shortest in patients on flu-
phenazine, but again the difference was not 
significant (Table 2).
Discussion
We found no differences in the two-year re-
hospitalization rates between the patients who 
were taking atypical or typical antipsychot-
ic agents either in the group with newly di-
agnosed or in the group with chronic schizo-
phrenia. No differences were found between 
the treatment groups of newly diagnosed 
schizophrenic patients in any of the demo-
graphic and clinical characteristics, except for 
duration of hospitalization, which was lon-
gest in the patients taking atypical antipsy-
chotic olanzapine. In our clinical practice, the 
first acute psychotic episode is initially treated 
with a typical antipsychotic drug and later on 
replaced by a new atypical antipsychotic drug, 
such as olanzapine. Thus, there is a possibility 
that patients on olanzapine were first admin-
istered typical antipsychotic drugs, which pro-
longed the duration of hospitalization. The 
duration of hospitalization was also signifi-
cantly longer in chronically ill schizophrenic 
patients taking olanzapine than in those tak-
ing other antipsychotic drugs.
In most studies investigating rehospitaliza-
tion rates of schizophrenic patients on differ-
ent antipsychotic drugs, the follow-up period 
did not last longer than a year (5,7,15,17,23). 
In our opinion, one-year follow-up may not be 
long enough to show a possible long-term re-
duction in rehospitalization rates. A follow-up 
period of at least two years may be necessary to 
clearly demonstrate the impact of atypical and 
typical antipsychotic drugs on rehospitaliza-
tion rates (26).
We did not find any significant difference 
in the rehospitalization rates between different 
treatment groups of patients newly diagnosed 
with schizophrenia, but we noticed that pa-
tients on clozapine were rehospitalized more 
often than other treatment groups during the 
first year of follow-up. Clozapine, according to 
the clinical guidelines (27), is not the medica-
Figure 4. Time to rehospitalization of patients with chronic schizo-
phrenia who were discharged on typical antipsychotic drugs fluphen-
azine (dashed line) or haloperidol (full line), or atypical antipsychotic 
drugs risperidone (dotted line), olanzapine (short-/long-dashed line), 
or clozapine (long-dashed line).
Figure 5. Time to rehospitalization of patients with chronic schizo-
phrenia who were discharged on typical antipsychotic medications 
(full line) or atypical antipsychotic medications (dashed line).
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tion of choice for the first psychotic episode. 
However, clozapine was administered to some 
of our patients with newly diagnosed schizo-
phrenia, most probably due to refractoriness 
to treatment. These patients were also rehos-
pitalized more often probably due to more se-
vere symptoms.
In our study, atypical antipsychotic drugs 
were significantly superior to typical antipsy-
chotic medications in the first year of follow-
up with respect to rehospitalization rate, but 
this difference disappeared during the sec-
ond year of follow-up period. This finding is 
contrary to the results obtained by Patel et al 
(23), who found typical antipsychotic medica-
tions to be superior to atypical ones over the 
first year of follow-up with respect to rehospi-
talization rate. However, they did not analyze 
patients with newly diagnosed shizophrenia 
separately from patients with chronic schizo-
phrenia.
In patients with chronic schizophrenia in 
our study, two-thirds were men. Most men 
with chronic schizophrenia were on haloperi-
dol; the youngest patients were on olanzapine. 
This is in line with the trend in our clinical 
practice that expensive atypical antipsychot-
ic drugs are more often prescribed to younger 
patients, whereas cheaper antipsychotic drugs, 
such as haloperidol, are more often prescribed 
to older patients and men. The duration of 
hospitalization was longest for chronically ill 
patients on olanzapine and shortest for pa-
tients on clozapine. Clozapine was the medi-
cation of choice for chronic and refractory cas-
es of schizophrenia, so these patients probably 
achieved remission sooner and were therefore 
discharged earlier from the hospital. There is 
a possibility that they were on clozapine even 
before hospitalization, but were hospitalized 
because they stopped taking the medication, 
received the same treatment, and achieved re-
mission sooner, with earlier discharge from 
the hospital.
All treatment groups of patients with 
chronic schizophrenia reached the plateau 
after one year of follow-up, and the num-
ber of rehospitalized patients in each treat-
ment group did not change significantly over 
the second year of follow-up. More precise-
ly, 48% of patients with chronic schizophre-
nia were rehospitalized by the end of the first 
year of follow-up and 49% by the end of the 
second year. Most patients who were not re-
hospitalized during the first year of follow-up 
were not rehospitalized during the second year 
of follow-up either. Although the possible rea-
sons for rehospitalization during the first year 
of follow-up remain to be determined, we may 
speculate that they include poor compliance, 
inadequate choice of drug, side effects, comor-
bidity (eg, addiction), and lack of family sup-
port. We noticed that, after the first 8 months, 
the number of rehospitalized patients taking 
clozapine did not change until the end of the 
two-year follow-up. In clinical practice, 6-8 
months is an optimal period to see if clozapine 
is an effective therapy (27-29).
We did not find significant differences in 
the rehospitalization rates of patients taking 
atypical or typical antipsychotic drugs over 
the two-year follow-up, which is in accordance 
with the findings reported by Lin et al (7) and 
Rabinowitz et al (17).
The novel aspect of our study is that pa-
tients with newly diagnosed schizophrenia 
were analyzed separately from patients with 
chronic schizophrenia. Previous studies ana-
lyzed either patients diagnosed with schizo-
phrenia all together or only those with either 
newly diagnosed or chronic schizophrenia. We 
believe that the patients with the first psychot-
ic decompensation and patients with multiple 
psychotic decompensations respond different-
ly to treatment and that their time to rehospi-
talization differs. Our finding that the propor-
tion of patients with chronic schizophrenia 
rehospitalized during the first year was the 
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same as the proportion rehospitalized during 
the second year of follow-up is in accordance 
with previous studies (17,30). On the oth-
er hand, fewer patients with newly diagnosed 
than with chronic schizophrenia were rehospi-
talized in the first and the second year of fol-
low-up in our study, which implies a better 
prognosis and longer remission, ie, time to re-
hospitalization. The first year rehospitalization 
rate of patients with newly diagnosed schizo-
phrenia was lower than that reported by Stras-
ser et al (5).
Our study has several limitations. The 
first limitation is inherent to the retrospec-
tive study design, ie, the patients were not ran-
domly assigned to the treatments. Second, the 
comparison involved clozapine, which is a 
drug reserved for the treatment of refractory 
schizophrenia. Third, discharge from the hos-
pital does not necessarily imply that the pa-
tient continued to take the prescribed drug in 
the outpatient setting. And fourthly, we did 
not evaluate the duration of treatment with 
antipsychotic drugs before discharge from the 
hospital. However, we had access to outpa-
tient prescription records for most of the pa-
tients and, given the sample size and relative-
ly high degree of completeness of data, we may 
consider our conclusions reliable.
In conclusion, we observed no significant 
differences in time-to-rehospitalization be-
tween different treatment groups during the 
two-year follow-up either in patients with 
newly diagnosed or chronic schizophrenia. The 
rehospitalization rates with atypical antipsy-
chotic drugs were similar to those with typical 
antipsychotic drugs for both the patients with 
newly diagnosed schizophrenia and patients 
with chronic schizophrenia, which indicates 
that the beneficial properties of modern atyp-
ical antipsychotic drugs have less favorable ef-
fects on rehospitalization rates than expected.
Future research should focus on other fac-
tors possibly associated with rehospitalization 
and choice of antipsychotic therapy, such as 
clinical presentation at baseline and intensi-
ty of illness, type of symptoms, presence of co-
morbidity, treatment adherence, history of pre-
vious trauma, and reasons for readmission.
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